Abstract

Precision health relies on the ability to assess disease risk at an individual level, detect early preclinical conditions and initiate preventive strategies. Recent technological advances in omics and wearable monitoring enable deep molecular and physiological profiling and may provide important tools for precision health. We explored the ability of deep longitudinal profiling to make health-related discoveries, identify clinically relevant molecular pathways and affect behavior in a prospective longitudinal cohort (n = 109) enriched for risk of type 2 diabetes mellitus. The cohort underwent integrative personalized omics profiling from samples collected quarterly for up to 8 years (median, 2.8 years) using clinical measures and emerging technologies including genome, immunome, transcriptome, proteome, metabolome, microbiome and wearable monitoring. We discovered more than 67 clinically actionable health discoveries and identified multiple molecular pathways associated with metabolic, cardiovascular and oncologic pathophysiology. We developed prediction models for insulin resistance by using omics measurements, illustrating their potential to replace burdensome tests. Finally, study participation led the majority of participants to implement diet and exercise changes. Altogether, we conclude that deep longitudinal profiling can lead to actionable health discoveries and provide relevant information for precision health.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Data availability

Raw omics data (transcriptome, immunome, proteome, metabolome, microbiome) included in this study are hosted on the NIH Human Microbiome 2 project site (https://portal.hmpdacc.org/) under the T2D project along with clinical laboratory data to 2016. Data from participants who have not consented to make their data public are available on dbGAP (accession phs001719.v1.p1). Additional data unique to this manuscript has been provided in the Supplementary Data files.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    National Research Council (US) Committee on a framework for developing a new taxonomy of disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (National Academies Press, 2012).

  2. 2.

    Li, X. et al. Digital health: tracking physiomes and activity using wearable biosensors reveals useful health-related information. PLoS Biol. 15, e2001402 (2017).

  3. 3.

    Chen, R. et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293–1307 (2012).

  4. 4.

    Price, N. D. et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat. Biotechnol. 35, 747–756 (2017).

  5. 5.

    Perkins, B. A. et al. Precision medicine screening using whole-genome sequencing and advanced imaging to identify disease risk in adults. Proc. Natl Acad. Sci. USA 115, 3686–3691 (2018).

  6. 6.

    Hall, H. et al. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 16, e2005143 (2018).

  7. 7.

    McConnell, M. V. et al. Feasibility of obtaining measures of lifestyle from a smartphone app: the myheart counts cardiovascular health study. JAMA Cardiol 2, 67–76 (2017).

  8. 8.

    Dinneen, S., Gerich, J. & Rizza, R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 327, 707–713 (1992).

  9. 9.

    Varghese, R. T. et al. Mechanisms underlying the pathogenesis of isolated impaired glucose tolerance in humans. J. Clin. Endocrinol. Metab. 101, 4816–4824 (2016).

  10. 10.

    Zhou, W. et al. Complex host-microbial dynamics in prediabetes revealed through longitudinal multi-omics profiling. Nature (in the press).

  11. 11.

    1000 Genomes Project Consortium. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).

  12. 12.

    Rego, S. et al. High frequency actionable pathogenic exome variants in an average-risk cohort. Cold Spring Harb. Mol. Case Stud. 4, a003178 (2018).

  13. 13.

    Pearson, E. R. et al. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362, 1275–1281 (2003).

  14. 14.

    Cersosimo, E., Solis-Herrera, C., Trautmann, M. E., Malloy, J. & Triplitt, C. L. Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr. Diabetes Rev. 10, 2–42 (2014).

  15. 15.

    Van Cauter, E., Mestrez, F., Sturis, J. & Polonsky, K. S. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance.Diabetes 41, 368–377 (1992).

  16. 16.

    Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).

  17. 17.

    Godsland, I. F., Jeffs, J. A. R. & Johnston, D. G. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 47, 1157–1166 (2004).

  18. 18.

    Kanat, M. et al. The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 34, 1006–1010 (2011).

  19. 19.

    Iikuni, N., Lam, Q. L. K., Lu, L., Matarese, G. & La Cava, A. Leptin and inflammation. Curr. Immunol. Rev. 4, 70–79 (2008).

  20. 20.

    Hamilton, J. A. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23, 403–408 (2002).

  21. 21.

    Reidy, S. P. & Weber, J. Leptin: an essential regulator of lipid metabolism. Comp. Biochem. Physiol. A 125, 285–298 (2000).

  22. 22.

    Guasch-Ferré, M. et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care 39, 833–846 (2016).

  23. 23.

    Twig, G. et al. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 36, 276–282 (2013).

  24. 24.

    Oliveira, A. G. et al. The role of hepatocyte growth factor (HGF) in insulin resistance and diabetes. Front. Endocrinol. 9, 503 (2018).

  25. 25.

    Mothe-Satney, I. et al. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes 61, 2311–2319 (2012).

  26. 26.

    Tsamardinos, I., Brown, L. E. & Aliferis, C. F. The max-min hill-climbing Bayesian network structure learning algorithm. Mach. Learn. 65, 31–78 (2006).

  27. 27.

    Lagani, V., Athineou, G., Farcomeni, A., Tsagris, M. & Tsamardinos, I. Feature selection with the R Package MXM: discovering statistically equivalent feature subsets. J. Stat. Softw. 80, 1–25 (2017).

  28. 28.

    McLaughlin, T. et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 139, 802–809 (2003).

  29. 29.

    Nowak, C. et al. Protein biomarkers for insulin resistance and type 2 diabetes risk in two large community cohorts. Diabetes 65, 276–284 (2016).

  30. 30.

    Apostolopoulou, M. et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care 41, 1235–1243 (2018).

  31. 31.

    Gomez-Arango, L. F. et al. Connections between the gut microbiome and metabolic hormones in early pregnancy in overweight and obese women. Diabetes 65, 2214–2223 (2016).

  32. 32.

    Kwo, P. Y., Cohen, S. M. & Lim, J. K. ACG clinical guideline: evaluation of abnormal liver chemistries. Am. J. Gastroenterol. 112, 18–35 (2017).

  33. 33.

    Hu, F. B. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25, 1129–1134 (2002).

  34. 34.

    Goff, D. C. Jr et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49–S73 (2014).

  35. 35.

    Kuznetsova, T. et al. Additive prognostic value of left ventricular systolic dysfunction in a population-based cohort. Circ. Cardiovasc. Imag. 9, e004661 (2016).

  36. 36.

    Wang, T. J. et al. Carotid intima-media thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation 108, 572–576 (2003).

  37. 37.

    Mitchell, G. F. et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 121, 505–511 (2010).

  38. 38.

    Moneghetti, K. J. et al. Applying current normative data to prognosis in heart failure: the fitness registry and the importance of exercise national database (FRIEND). Int. J. Cardiol. 263, 75–79 (2018).

  39. 39.

    Hall, K. T. et al. Polymorphisms in catechol-O-methyltransferase modify treatment effects of aspirin on risk of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 34, 2160–2167 (2014).

  40. 40.

    Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.Nat. Genet. 50, 524–537 (2018).

  41. 41.

    Cross, D. S. et al. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts. Curr. Med. Res. Opin. 28, 1819–1830 (2012).

  42. 42.

    Ma, H., Calderon, T. M., Fallon, J. T. & Berman, J. W. Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis 164, 79–87 (2002).

  43. 43.

    Bell, E. J. et al. Hepatocyte growth factor is positively associated with risk of stroke: the MESA (Multi-Ethnic Study of Atherosclerosis). Stroke 47, 2689–2694 (2016).

  44. 44.

    Chen, X. & Devaraj, S. Monocytes from metabolic syndrome subjects exhibit a proinflammatory M1 phenotype. Metab. Syndr. Relat. Disord. 12, 362–366 (2014).

  45. 45.

    Elkind, M. S. et al. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis 180, 181–187 (2005).

  46. 46.

    Porez, G., Prawitt, J., Gross, B. & Staels, B. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 53, 1723–1737 (2012).

  47. 47.

    Berry, C. E. & Hare, J. M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physiol. 555, 589–606 (2004).

  48. 48.

    Sane, D. C., Kontos, J. L. & Greenberg, C. S. Roles of transglutaminases in cardiac and vascular diseases. Front. Biosci. 12, 2530–2545 (2007).

  49. 49.

    Wollert, K. C., Kempf, T. & Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem. 63, 140–151 (2017).

  50. 50.

    Klok, M. D., Jakobsdottir, S. & Drent, M. L. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev. 8, 21–34 (2007).

  51. 51.

    Charbonneau, B. et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 60, 882–889 (2012).

  52. 52.

    Przewoznik, M. et al. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer. J. Immunother. 35, 217–222 (2012).

  53. 53.

    Haabeth, O. A. W. et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun. 2, 240 (2011).

  54. 54.

    Ding, Q. et al. CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med. 5, 3246–3259 (2016).

  55. 55.

    Rolny, C. et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31–44 (2011).

  56. 56.

    Johnson, L. D. S., Goubran, H. A. & Kotb, R. R. Histidine rich glycoprotein and cancer: a multi-faceted relationship. Anticancer Res. 34, 593–603 (2014).

  57. 57.

    Go, R. S., Gundrum, J. D. & Neuner, J. M. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin. Lymphoma Myeloma Leuk. 15, 177–186.e4 (2015).

  58. 58.

    Turesson, I. et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123, 338–345 (2014).

  59. 59.

    Alqvist E. et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 6, P361–P369 (2018).

  60. 60.

    Cauwenberghs, N. et al. Relation of insulin resistance to longitudinal changes in left ventricular structure and function in a general population. J. Am. Heart Assoc. 7, e008315 (2018).

  61. 61.

    Piening, B. D. et al. Integrative personal omics profiles during periods of weight gain and loss. Cell Syst. 6, 157–170.e8 (2018).

  62. 62.

    Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clinical Pharmacol. Ther. 92, 414–417 (2012).

  63. 63.

    Li, J. et al. Decoding the genomics of abdominal aortic aneurysm. Cell 174, 1361–1372.e10 (2018).

  64. 64.

    Douglas, P. S. et al. The future of cardiac imaging: report of a think tank convened by the american college of cardiology. JACC Cardiovasc. Imag. 9, 1211–1223 (2016).

  65. 65.

    Buhr, S. Apple’s Watch isn’t the first with an EKG reader but it will matter to more consumers. TechCrunch https://techcrunch.com/2018/09/12/apples-watch-isnt-the-first-with-an-ekg-reader-but-it-will-matter-to-more-consumers/ (2018).

  66. 66.

    Omer, W., Naveed, A. K., Khan, O. J. & Khan, D. A. Role of cytokine gene score in risk prediction of premature coronary artery disease. Genet. Test. Mol. Biomarkers 20, 685–691 (2016).

  67. 67.

    Integrated Molecular Pathway Level Analysis (accessed 27 December 2018); http://impala.molgen.mpg.de/

  68. 68.

    Szklarczyk, D. et al. STRINGv10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).

  69. 69.

    The Integrative Human Microbiome Project. Dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276–289 (2014).

  70. 70.

    Cohen, S. & Williamson, G. in The Social Psychology of Health (eds Spacapan, S. and Oskamp, S.) 31–67 (Sage Publications, 1988).

  71. 71.

    Slavich, G. M. & Shields, G. S. Assessing lifetime stress exposure using the Stress and Adversity Inventory for adults (Adult STRAIN): an overview and initial validation. Psychosom. Med. 80, 17–27 (2018).

  72. 72.

    Lee, P. H., Macfarlane, D. J., Lam, T. H. & Stewart, S. M. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int. J. Behav. Nutr. Phys. Act. 8, 115 (2011).

  73. 73.

    Pei, D., Jones, C. N. O., Bhargava, R., Chen, Y.-D. I. & Reaven, G. M. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 37, 843–845 (1994).

  74. 74.

    Lam, H. Y. K. et al. Detecting and annotating genetic variations using the HugeSeq pipeline. Nat. Biotechnol. 30, 226–229 (2012).

  75. 75.

    Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SFv2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249–255 (2017).

  76. 76.

    Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).

  77. 77.

    Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 1–21 (2014).

  78. 78.

    Luminex Multiplex Analysis (Stanford Human Immune Monitoring Core, 2018); http://iti.stanford.edu/content/dam/sm/iti/documents/himc/protocols/LuminexMultiplexAnalysisprotocol030213.doc

  79. 79.

    Contrepois, K., Jiang, L. & Snyder, M. Optimized analytical procedures for the untargeted metabolomic profiling of human urine and plasma by combining hydrophilic interaction (HILIC) and reverse-phase liquid chromatography (RPLC)-mass spectrometry. Mol. Cell. Proteomics 14, 1684–1695 (2015).

  80. 80.

    Contrepois, K. et al. Cross-platform comparison of untargeted and targeted lipidomics approaches on aging mouse plasma. Sci. Rep. 8, 17747 (2018).

  81. 81.

    Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 28, 1–39.e14 (2015).

  82. 82.

    Wilson, P. W. F. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).

  83. 83.

    Smith, D. A. In adults without CVD, the MESA score, including coronary artery calcium, predicted 10-y risk for CHD events. Ann. Intern. Med. 164, JC35 (2016).

  84. 84.

    McClelland, R. L. et al. 10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the mesa (multi-ethnic study of atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J. Am. Coll. Cardiol. 66, 1643–1653 (2015).

  85. 85.

    Lee, K. K., Cipriano, L. E., Owens, D. K., Go, A. S. & Hlatky, M. A. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation 122, 1478–1487 (2010).

  86. 86.

    Myers, J., Bader, D., Madhavan, R. & Froelicher, V. Validation of a specific activity questionnaire to estimate exercise tolerance in patients referred for exercise testing. Am. Heart J. 142, 1041–1046 (2001).

  87. 87.

    Arena, R., Myers, J., Aslam, S. S., Varughese, E. B. & Peberdy, M. A. Technical considerations related to the minute ventilation/carbon dioxide output slope in patients with heart failure. Chest 124, 720–727 (2003).

  88. 88.

    Kaminsky, L. A., Imboden, M. T., Arena, R. & Myers, J. Reference standards for cardiorespiratory fitness measured with cardiopulmonary exercise testing using cycle ergometry: data from the fitness registry and the importance of exercise national database (FRIEND) Registry. Mayo Clin. Proc. 92, 228–233 (2017).

  89. 89.

    Hovorka, R., Soons, P. A. & Young, M. A. ISEC: a program to calculate insulin secretion. Comput. Methods Programs Biomed. 50, 253–264 (1996).

  90. 90.

    Kamburov, A., Cavill, R., Ebbels, T. M. D., Herwig, R. & Keun, H. C. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 27, 2917–2918 (2011).

  91. 91.

    Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).

  92. 92.

    Fruchterman, T. M. J. & Reingold, E. M. Graph drawing by force-directed placement. Softw. Pract. Exp. 21, 1129–1164 (1991).

  93. 93.

    Montagna, P. A. Using SAS to manage biological species data and calculate diversity indices. in 2014 SCSUG Educational Forum (South Central SAS Users Group, 2014).

  94. 94.

    Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).

  95. 95.

    Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).

  96. 96.

    Bokulich, N. A. et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2’s q2-feature-classifier plugin. Microbiome 6, 90 (2018).

  97. 97.

    Callahan, B. J., McMurdie, P. J. & Holmes, S. P. Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J. 11, 2639 (2017).

  98. 98.

    Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).

Download references

Acknowledgements

Our work was supported by grants from the National Institutes of Health (NIH) Human Microbiome Project (HMP) 1U54DE02378901 (G.M.W. and M.P.S.), an NIH grant no. R01 DK110186-03 (T.L.M.), a NIH National Center for Advancing Translational Science Clinical and Translational Science Award (no. UL1TR001085). This work used the Genome Sequencing Service Center by the Stanford Center for Genomics and Personalized Medicine Sequencing Center (supported by NIH grant no. S10OD020141), the Diabetes Genomics Analysis Core and the Clinical and Translational Core of the Stanford Diabetes Research Center (NIH grant no. P30DK116074). S.M.S.-F.R. was supported by a Department of Veteran Affairs Office of Academic Affiliations Advanced Fellowship in Spinal Cord Injury Medicine and a NIH Career Development Award no. K08 ES028825. G.M.S. was supported by NIH grant no. K08 MH103443. D.H. was supported by a Stanford School of Medicine Dean’s Postdoctoral Fellowship and a Stanford Center for Computational, Evolutionary and Human Genomics Fellowship. M.R.S. was supported by grant nos. P300PA_161005 and P2GEP3_151825 from the Swiss National Science Foundation (SNSF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, the Department of Veteran Affairs, or the SNSF. We thank S. Chen and B. Lee for their work in metabolomics data production. A. Breschi generously shared her code for the ISR calculations. Finally, we thank the iPOP participants who generously gave their time and biological samples.

Author information

Author notes

  1. These authors contributed equally: Sophia Miryam Schüssler-Fiorenza Rose, Kévin Contrepois.

Affiliations

  1. Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA

    • Sophia Miryam Schüssler-Fiorenza Rose
    • , Kévin Contrepois
    • , Wenyu Zhou
    • , Tejaswini Mishra
    • , Orit Dagan-Rosenfeld
    • , Ariel B. Ganz
    • , Jessilyn Dunn
    • , Daniel Hornburg
    • , Shannon Rego
    • , Dalia Perelman
    • , Sara Ahadi
    • , M. Reza Sailani
    • , Melanie Ashland
    • , Monika Avina
    • , Patricia Limcaoco
    •  & Michael P. Snyder
  2. Spinal Cord Injury Service, Veteran Affairs Palo Alto Health Care System, Palo Alto, CA, USA

    • Sophia Miryam Schüssler-Fiorenza Rose
  3. Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA

    • Sophia Miryam Schüssler-Fiorenza Rose
  4. Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA

    • Kegan J. Moneghetti
    • , Jeffrey W. Christle
    • , Francois Haddad
    •  & Michael P. Snyder
  5. Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

    • Kegan J. Moneghetti
    • , Jeffrey W. Christle
    •  & Francois Haddad
  6. Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Australia

    • Kegan J. Moneghetti
  7. Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA, USA

    • Samson Mataraso
  8. Department of Bioengineering, University of California, Berkeley, Berkeley, CA, USA

    • Samson Mataraso
  9. Mobilize Center, Stanford University, Stanford, CA, USA

    • Jessilyn Dunn
  10. The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA

    • Yanjiao Zhou
    • , Shana R. Leopold
    • , George M. Weinstock
    •  & Erica Sodergren
  11. Department of Medicine, University of Connecticut Health, Farmington, CT, USA

    • Yanjiao Zhou
  12. Bakar Computational Health Sciences Institute and Department of Pediatrics, University of California, San Francisco, CA, USA

    • Jieming Chen
    •  & Atul J. Butte
  13. Department of Bioengineering, Stanford University, Stanford, CA, USA

    • Camilo Ruiz
  14. Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA

    • Marilyn Tan
    •  & Tracey L. McLaughlin
  15. Cousins Center for Psychoneuroimmunology and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA

    • George M. Slavich

Authors

  1. Search for Sophia Miryam Schüssler-Fiorenza Rose in:

  2. Search for Kévin Contrepois in:

  3. Search for Kegan J. Moneghetti in:

  4. Search for Wenyu Zhou in:

  5. Search for Tejaswini Mishra in:

  6. Search for Samson Mataraso in:

  7. Search for Orit Dagan-Rosenfeld in:

  8. Search for Ariel B. Ganz in:

  9. Search for Jessilyn Dunn in:

  10. Search for Daniel Hornburg in:

  11. Search for Shannon Rego in:

  12. Search for Dalia Perelman in:

  13. Search for Sara Ahadi in:

  14. Search for M. Reza Sailani in:

  15. Search for Yanjiao Zhou in:

  16. Search for Shana R. Leopold in:

  17. Search for Jieming Chen in:

  18. Search for Melanie Ashland in:

  19. Search for Jeffrey W. Christle in:

  20. Search for Monika Avina in:

  21. Search for Patricia Limcaoco in:

  22. Search for Camilo Ruiz in:

  23. Search for Marilyn Tan in:

  24. Search for Atul J. Butte in:

  25. Search for George M. Weinstock in:

  26. Search for George M. Slavich in:

  27. Search for Erica Sodergren in:

  28. Search for Tracey L. McLaughlin in:

  29. Search for Francois Haddad in:

  30. Search for Michael P. Snyder in:

Contributions

S.M.S.-F.R., M.P.S., F.H., K.C., K.M., T.M. and W.Z. contributed to the conceptualization. S.M.S.-F.R., K.C., F.H., M.P.S., T.M., K.M., S.M., W.Z. and S.R. contributed to the methodology. K.C. (ASCVD biomarkers), D.H. (Lipidomics), A.B.G. (Microbiome DADA2 processing), T.M., M.A. and W.Z. (OGTT C-peptide and insulin) contributed to omics generation and/or processing. S.M.S.-F.R., K.C., T.M., W.Z., J.D., M.A., J.W.C., E.S. and P.L. contributed to data curation. K.C., S.M.S.-F.R., T.M., K.M., F.H. and M.P.S. contributed to visualization. S.M.S.-F.R., K.C., T.M., S.M., K.M., O.D.-R., S.R., J.C. and C.R. contributed to formal analysis. S.M.S.-F.R., K.C. and M.P.S. contributed to project administration. M.P.S. and F.H. contributed to supervision. S.M.S.-F.R., F.H., K.C., K.M. and M.P.S. contributed to writing and preparing the original draft. S.M.S.-F.R., K.C., K.M., F.H., M.P.S., W.Z., A.B.G., D.H., J.D., G.M.S, T.M., M.T., D.P., T.L.M., A.J.B., M.R.S. and S.A. contributed to review and editing. K.M., F.H. and J.W.C. contributed to cardiovascular clinical data collection and investigation. W.Z., S.R., M.A., P.L., D.P., M.T., T.L.M. and S.M.S.-F.R. contributed to iPOP/iHMP clinical data collection/investigation. W.Z., S.R.L, M.P.S., T.L.M., E.S. and G.M.W. contributed to iPOP/iHMP project administration. K.C. (metabolomics), S.A. (proteomics), M.R.S. (DNA, RNA-seq), W.Z. (microbiome, cytokines, and overall omics data), Y.Z. (microbiome), T.M. and D.H. (batch correction methodology for proteomics) contributed to iPOP/iHMP omics raw data processing. M.P.S., G.M.W., T.L.M. and E.S. contributed to iPOP/iHMP funding acquisition.

Competing interests

M.P.S. is a cofounder of Personalis, SensOmics, January, Filtricine, Qbio and Akna and an inventor on provisional patent number 62/814,746 ‘Methods for evaluation and treatment of glycemic dysregulation and applications thereof’. S.M.S.-F.R., K.C., W.Z., T.M. and S.M. are also listed as inventors. A.J.B. reports grants and non-financial support from Progenity, grants and personal fees from NIH (multiple institutes) and Genentech, and grants from L’Oreal, personal fees from NuMedii, Personalis, Lilly, Assay Depot, Geisinger Health, GNS Healthcare, uBiome, Roche, Wilson Sonsini Goodrich & Rosati, Orrick, Herrington & Sutcliffe, Verinata, 10x Genomics, Pathway Genomics, Guardant Health, Gerson Lehrman Group, Nuna Health, Samsung, Capital Royalty Group, Optum Labs, Pfizer, AbbVie, Bayer, Three Lakes Partners, HudsonAlpha, Tensegrity, Westat, FH Foundation, WuXi, FlareCapital, Helix, Roam Insights, Autodesk, Regenstrief Institute, American Medical Association, Precision Medicine World Conference, and Mars during the conduct of the study. A.J.B. has pending patent Atul J. Butte, Keiichi Kodama, Methods for diagnosis and treatment of non-insulin dependent diabetes mellitus, published August 4, 2011, WO2011094731 and US20130071408; patent Joel T. Dudley, Atul J. Butte, Method and System for Computing and Integrating Genetic and Environmental Health Risks for a Personal Genome, published April 26, 2012, US20120101736 with royalties paid to Personalis; patent Joel T. Dudley, Atul J. Butte, Method And System For Functional Evolutionary Assessment Of Genetic Variants, published April 11, 2013, US20130090909 with royalties paid to Personalis; patent Konrad Karczewski, Michael Snyder, Atul J. Butte, Joel T. Dudley, Eurie Hong, Alan Boyle, J. Michael Cherry, Method and System for Assessment of Regulatory Variants in a Genome, published May 9, 2013, US20130116931 with royalties paid to Personalis; and patent Frederick Dewey, Euan Ashley, Carlos Daniel Bustamante, Atul Butte, Jake Byrnes, Rong Chen, Phased Whole Genome Genetic Risk In A Family Quartet, published March 28, 2013, US20130080068, with royalties paid to Personalis; Stanford University pays royalties each year on licensed intellectual property.

Corresponding authors

Correspondence to Francois Haddad or Michael P. Snyder.

Extended data

  1. Extended Data Fig. 1 Integrated personalized omics profiling cohort flow chart and genetic ancestry.

    a, The flow chart demonstrates recruitment and enrollment of the iPOP cohort. b, PCA plot showing the ancestries of 72 participants. The reference includes 2,504 samples from the 1,000GP11. Each filled circle is a 1,000GP sample, colored by the super-population of ancestral origin, namely African (AFR; red), admixed American (AMR; purple), East Asian (EAS; green), European (EUR; cyan) and South Asian (SAS; orange). Each black symbol is an individual from the study, which we categorized by self-reported ethnicity consistent with the 1,000GP super-population definitions, namely AFR (black filled circle), AMR (black filled triangle), EAS (black filled square), EUR (black plus sign) and South Asian (a checked box). We see that the individuals in our study have self-reported ancestries generally clustering in the super-population reference panel from the 1,000GP. Source Data

  2. Extended Data Fig. 2 Comparison of diabetic metrics in categorizing individuals when performed at the same time and HbA1C trajectories.

    a, Overlap of FPG and hemoglobin A1C (HbA1C) categories when simultaneously measured. FPG impaired: 1.0 mg ml−1 ≤ FPG < 1.26 mg ml−1; diabetic range: FPG ≥ 1.26 mg ml−1; HbA1C impaired: 5.7% ≤ HbA1C < 6.5%; diabetic range: HbA1C ≥ 6.5%. b, Overlap of FPG and 2-hour OGTT when simultaneously measured. FPG ranges as above. OGTT impaired: 1.40 mg ml−1 ≤ OGTT < 2.00 mg ml−1; diabetic range ≥2.00 mg ml−1. c, Longitudinal patterns of changes in Hemoglobin A1C (HbA1C) over time. Six different patterns could be characterized including: 1, participants who remained in the normal range the entire study (Group 1, n = 51); 2, participants who progressed from normal to prediabetic (Group 2, n = 5); 3, participants who went from prediabetic to normal (Group 3, n = 10); 4, participants whose HbA1C went back and forth from normal to prediabetic (Group 4, n = 21); 5, participants whose HbA1C laboratory results were predominantly in the prediabetic range (Group 5, n = 14) and 6, participants whose HbA1C crossed into the diabetic range (Group 6, n = 8). The red lines represent the overall penalized b-spline of participants’ data in each category. Source Data

  3. Extended Data Fig. 3 Additional individual longitudinal trajectories for diabetic measures.

    Diabetic-range metrics are indicated in red. ae, Diabetic-range OGTT (a), Diabetic-range FPG (b,c), undiagnosed DM at study entry (HbA1C) (d), Initial abnormality HbA1C (e). Note this person had two HbA1C measurements on the same day at two different laboratories and was started on medication based on the higher measurement. f,g, Bouncer with diabetic-range HbA1C and OGTT (f) and SSPG decrease with lifestyle change (g). Source Data

  4. Extended Data Fig. 4 Longitudinal microbiome trajectories in diabetes.

    a,b, Longitudinal weight, gut microbial Shannon diversity and phylum proportion changes in participants ZNDMXI3 (a) and ZNED4XZ (b). c, Longitudinal changes in genus proportion (ZNDMXI3). d,e, Microbiome outliers (95th percentile) at the latest microbiome sample time point in participants ZNDMXI3 (d) and ZNED4XZ (e). Microbial abundance is scaled by row with low (blue) and high (red) abundance. Source Data

  5. Extended Data Fig. 5 Multi-omics of glucose metabolism and inflammation.

    a, Proteins and metabolites associated with HbA1C, FPG and hsCRP using healthy-baseline and dynamic linear mixed models. Healthy-baseline models (HbA1C n = 101, samples 560; FPG n = 101, samples 563; hsCRP n = 98, samples 518) account for repeated measures at healthy time points. Dynamic models are similar models except that analytes are normalized across individuals to the first measurement and all time points in the study are used (HbA1C n = 94, samples = 836; FPG n = 94, samples = 843; hsCRP n = 92, samples 777). Individual analyte P values were determined using a two-sided t-test. Multiple testing correction was performed and molecules were considered significant when Benjamini–Hochberg FDR < 0.2. Model estimates were normalized in each condition so the maximum value equal to 1 and the minimal value equal to −1. b, Integrative pathway analysis using IMPaLa67 of proteins and metabolites associated with HbA1C (n = 101, samples 560), FPG (n = 101, samples 563) and hsCRP (n = 98, samples 518) as determined by the healthy-baseline models (Benjamini–Hochberg FDR < 0.2 at molecule level) that matched to known pathways. Significance of pathways for proteins and metabolites separately is determined by the hypergeometric test (one-sided) followed by Fisher’s combined probability test (one-sided) to determine combined pathway significance (Benjamini–Hochberg FDR < 0.05; n’s of proteins and metabolites for each pathway are provided in Supplementary Tables 9, 11 and 13).

  6. Extended Data Fig. 6 Outlier Analysis of RNA-seq data.

    a, Number of outlier RNA molecules (95th percentile) in each participant. Outlier analysis was performed on Z scores calculated on the median expression level of each gene at healthy visits in individuals with at least three healthy visits (n = 63). The box is defined as 25th and 75th quartile. The upper whisker extends to 1.5 times the interquartile range from the box and the lower whisker to the lowest data point. The horizontal bar in the box is the median value. b, Selected clinical laboratory and metabolite trajectories (seven measurement time points) for participant ZJTKAE3 showing a concomitant increase of bile acids and glutamyl dipeptides with ALT (alanine aminotransferase) and AST (aspartate aminotransferase). Source Data

  7. Extended Data Fig. 7 Multidimensional cardiac risk assessment.

    a, Distribution of ASCVD risk scores (n = 35 participants, 36 measurements) and cardiovascular imaging and physiology measures that have been established as cardiovascular risk markers. (Abbreviations: RWT-relative wall thickness, LV GLS-left ventricular global longitudinal strain, E/e’ - ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e’), PWV-pulse wave velocity). Please note that thresholds for PWV are age-related. Box plots were derived to display quartiles (Q1, median, Q3) with the upper whisker being Q3 + 1.5 × (interquartile range) and the lower whisker extending to Q1 − 1.5 × (interquartile range) or the lowest data point. b, Ultrasound of carotid plaque (6 participants out of 35 had an ultrasound finding of carotid plaque) and relative distribution of ASCVD risk score, HbA1C and LV GLS in function of presence or absence of carotid plaque (Student’s t-test (two-sided) was used to evaluate differences between groups; n = 35, 36 measurements) (Abbreviations: CCA-common carotid artery; IJV-internal jugular vein). Error bars represent one standard deviation from the mean (upper edge of box). c, Correlation network of selected metrics collected during cardiovascular assessment (Spearman correlation (two-sided) with q < 0.2; n = 35 participants with 36 measurements). d, Composite Z score of ZOBX723 (unstable angina with stent placement) and ZNED4XZ (mild stroke with full recovery and transition to diabetes). For ZOBX723, day 829 occurred 3 weeks post-stent placement. Day 679 was a mid-infection time point. For ZNED4XZ, day 699 was the time point before the participant’s transition to diabetes and day 846 was the first diabetic time point. The stroke occurred on day 307 for this individual. Gray dots represent Z scores of other participants (n = 101 with 859 samples). e, Violin plot showing the same data as d (n = 101 with 859 samples). The box plot shows the first (lower edge of box), median (middle line) and third (upper edge of box) quartiles. The upper whisker is the third quartile + 1.5 × (interquartile range) and the lower whisker is the lowest data point. Source Data

Supplementary information

  1. Reporting Summary

  2. Supplementary Tables

    Supplementary Tables 0–28

  3. Supplementary Data

    Data Tables 1–24

Source data

About this article

Publication history

Received

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41591-019-0414-6

Further reading